Enterprise Value
188.9M
Cash
252.6M
Avg Qtr Burn
-33.96M
Short % of Float
6.55%
Insider Ownership
4.42%
Institutional Own.
85.84%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2b Data readout | ||
Lirentelimab (AK002) Details Atopic dermatitis | Phase 2 Data readout | |
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Esophagitis | Failed Discontinued | |
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Duodentitis , Eosinophilic Gastritis | Failed Discontinued |